MedPath

To assess the Artificial Intelligence Software in detection of Diabetic Retinopathy

Not yet recruiting
Conditions
Type 2 diabetes mellitus with ophthalmic complications,
Registration Number
CTRI/2020/03/024000
Lead Sponsor
Dr S Sivaranjani
Brief Summary

Purpose:

The purpose of the study is to simplify the screening of Diabetic Retinopathy and to create public awareness. Artificial intelligence can play a unique role in public health screeningfor detection of diabetic Retinopathy**.** Evaluation of fundusphotos through an offline DR Grading software may be an effective tool in ascreening setting to determine critical levels of diabetic retinopathy forprompt specialist referral.

Findings:

There are no findings yet.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
250
Inclusion Criteria

All the diabetic patients visiting the DR screening camps with pupil size 3 mm or more, cataract with grade senile immature cataract with nuclear sclerosis II (NSII) and with clear cornea.

Exclusion Criteria

Patients with macular or leucomatous corneal opacity, cataract with grade more than senile immature cataract with nuclear sclerosis II.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the accuracy of grading done by Artificial IntelligenceOnce the recruitment is completed, the images will be sent to Retina Specialist and assessed. Time point will be 3 months.
Secondary Outcome Measures
NameTimeMethod
To assess the number of patients with Diabetic Retinopathy in patients who come for a Diabetic Retinopathy camp.By the end of recruitment - 3 months

Trial Locations

Locations (1)

Aravind Eye Hospital Pondicherry

🇮🇳

Pondicherry, PONDICHERRY, India

Aravind Eye Hospital Pondicherry
🇮🇳Pondicherry, PONDICHERRY, India
Dr S Sivaranjani
Principal investigator
9943759150
drsivaranjani.s@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.